Variant · Expression
IGF2 Overexpression
CI-VAR-00003127Explore in graph →CIViC 156
Curated evidence
Evidence by cancer (5 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24727326
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Ovarian Neoplasm1 | ||||||||
| IGF2 Overexpression | Ganitumab | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID6972Treatment of mice bearing established OV-90 xenografts with ganitumab significantly inhibited tumor growth in a dose-dependent manner. Ganitumab dosed at 30, 100, and 300 µg twice per week resulted in… (full text at CIViC) PMID 24727326 · Beltran et al., 2014 · Open in CIViC | civic |
| Malignant Prostate Neoplasm3 | ||||||||
| IGF2 Overexpression | Cabazitaxel + LinsitinibCombination | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12428OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available